Silo Pharma, Inc.
NasdaqCM:SILO Rapporto sulle azioni
Silo Pharma Gestione
Gestione criteri di controllo 2/4 Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Eric Weisblum
Amministratore delegato
Percentuale dello stipendio del CEO 61.5% Mandato del CEO 11.8yrs Proprietà del CEO 4.0% Durata media del management Nessun dato Durata media del Consiglio di amministrazione 4yrs
Aggiornamenti recenti sulla gestione
Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024 Sep 20
Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024 Sep 19
Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023 Oct 25
Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023 Oct 24
High number of new and inexperienced directors Nov 16
High number of new and inexperienced directors Nov 01
Mostra tutti gli aggiornamenti
Silo Pharma, Inc. Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant Nov 02
Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024 Sep 20
Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024 Sep 19
Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.32 loss in 2Q 2023) Aug 15 Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.100005 million. Jul 23
Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.100005 million. Jul 20
Silo Pharma, Inc. announced that it has received $2.077409 million in funding Jun 13
New minor risk - Shareholder dilution Jun 09 Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.000002 million. Jun 08
Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.000002 million. Jun 06
New major risk - Share price stability Jun 05
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety Jun 05
Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention May 23
First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.29 loss in 1Q 2023) May 15
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment Apr 24
Full year 2023 earnings: EPS misses analyst expectations Mar 26
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery Feb 16
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology Feb 03
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study Jan 25
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD Jan 05
New minor risk - Share price stability Nov 29
Third quarter 2023 earnings: EPS exceeds analyst expectations Nov 16
Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD Nov 09
Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023 Oct 25
Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023 Oct 24
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis Oct 17
Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA Sep 21
Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD Sep 14
Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.33 loss in 2Q 2022) Aug 13
First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.31 loss in 1Q 2022) May 14
Silo Pharma, Inc. Announces Spc-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’S Disease May 10
Full year 2022 earnings released: US$1.71 loss per share (vs US$1.45 profit in FY 2021) Mar 27
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer's Feb 15
Silo Pharma, Inc. (NasdaqCM:SILO) announces an Equity Buyback for $1 million worth of its shares. Feb 01
Silo Pharma, Inc. Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation Jan 12
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis Dec 31
Silo Pharma, Inc. Initiates Study of Novel Joint Homing Peptide in Human Tissue Nov 22
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$0.49 loss per share (vs US$3.28 profit in 3Q 2021) Nov 13
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation Nov 12
Investor sentiment deteriorated over the past week Nov 11
High number of new and inexperienced directors Nov 01
Silo Pharma, Inc. Announces Data Supporting Therapeutic Potential of SPC -14 for Alzheimer's Disease in Pre-Clinical Study Oct 21
Silo Pharma spikes on pre-clinical data for Alzheimer's candidate Oct 20
Investor sentiment improved over the past week Oct 11
High number of new and inexperienced directors Oct 11
Silo Pharma Initiates Toxicity Study of Proprietary Ketamine Formulation for Treatment of Fibromyalgia Oct 11
Silo Pharma, Inc. Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology Oct 04
Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia Oct 03
Silo Pharma, Inc. Announces Positive Results from its Topically Administered Formulation of Ketamine Jul 28
Silo Pharma, Inc. Announces Positive Results in Subcutaneous Delivery of Its Novel Liposomes to Treat Arthritic Patients Jul 13
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study May 20
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study Apr 21
Silo Pharma, Inc. Enters into Exclusive Option Agreement with the University of Maryland, Baltimore for Patented Homing Peptides Targeting Rheumatoid Arthritis Mar 05
Silo Pharma, Inc. Enters into A Master License Agreement with the University of Maryland, Baltimore Feb 17
Silo Pharma Inc. announced that it expects to receive $4.276 million in funding Feb 11
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease Jan 28
Silo Pharma Inc. Announces Licensing Agreement with Aikido Pharma Inc Jan 12
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities Jan 08
Silo Pharma, Inc. Appoints Charles B. Nemeroff to Scientific Advisory Board Dec 17
Silo Pharma Inc. Appoints Peter Hendricks to its Scientific Advisory Board Dec 10
Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’S Disease Dec 03
Silo Pharma, Inc. Names Joshua Woolley to Newly Formed Scientific Advisory Board Nov 17
Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Matthew Johnson of John Hopkins University Nov 10
Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides Oct 14
Silo Pharma, Inc. Appoints Kevin Muñoz to Board of Directors Oct 07
Analisi delle retribuzioni degli amministratori delegati Come è cambiata la remunerazione di Eric Weisblum rispetto agli utili di Silo Pharma? Data Compenso totale Stipendio Guadagni aziendali Jun 30 2024 n/a n/a -US$3m
Mar 31 2024 n/a n/a -US$4m
Dec 31 2023 US$569k US$350k -US$4m
Sep 30 2023 n/a n/a -US$4m
Jun 30 2023 n/a n/a -US$5m
Mar 31 2023 n/a n/a -US$4m
Dec 31 2022 US$332k US$223k -US$4m
Sep 30 2022 n/a n/a -US$3m
Jun 30 2022 n/a n/a US$4m
Mar 31 2022 n/a n/a US$4m
Dec 31 2021 US$345k US$175k US$3m
Sep 30 2021 n/a n/a US$3m
Jun 30 2021 n/a n/a -US$4m
Mar 31 2021 n/a n/a -US$5m
Dec 31 2020 US$725k US$115k -US$3m
Sep 30 2020 n/a n/a -US$3m
Jun 30 2020 n/a n/a -US$2m
Mar 31 2020 n/a n/a -US$1m
Dec 31 2019 US$199k US$91k -US$1m
Sep 30 2019 n/a n/a -US$1m
Jun 30 2019 n/a n/a -US$1m
Mar 31 2019 n/a n/a -US$1m
Dec 31 2018 US$60k n/a -US$969k
Sep 30 2018 n/a n/a -US$290k
Jun 30 2018 n/a n/a -US$611k
Mar 31 2018 n/a n/a -US$371k
Dec 31 2017 US$60k n/a US$357k
Compensazione vs Mercato: La retribuzione totale di Eric ($USD 569.01K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 647.72K ).
Compensazione vs guadagni: La retribuzione di Eric è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO Mr. Eric Weisblum has been the Chief Executive Officer and Chairman of the Board of Silo Pharma, Inc. (formerly known as, Uppercut Brands Inc.) since November 27, 2015 and has been its President and Direct ... Show more
Membri del Consiglio di amministrazione Nome Posizione Mandato Compensazione Proprietà Chairman 11.8yrs US$569.01k 4.02% $ 221.9k Member of Scientific Advisory Board 3.9yrs Nessun dato Nessun dato Independent Director 4.8yrs US$45.00k 0% $ 0 Independent Director 4.1yrs US$25.00k 0% $ 0 Member of Scientific Advisory Board 4yrs Nessun dato Nessun dato Independent Director 2.2yrs US$25.00k Nessun dato
Mostra di più
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SILO sono considerati esperti (durata media dell'incarico 4 anni).
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}